Bioassociate Reports
48 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Bioassociate
Scoop.it!

FDA Stock Catalysts: Drug Approval Calendar August – December 2013 Bioassociate Life Science & Biotech Consulting

FDA Stock Catalysts: Drug Approval Calendar August – December 2013 Bioassociate Life Science & Biotech Consulting | Bioassociate Reports | Scoop.it

Stocks are crashing and soaring ahead of scheduled U.S. Food and Drug Administration (FDA) drug approvals in Q3 - Q4 2013. Twelve promising compounds remain on the FDA drug approval calendar in August - December of this year. If approved, the drugs can finally reach the market and begin to generate revenue for their developers, who have likely spent millions on the drug's development. 

Many of the drugs' stocks are on the increase running up to the FDA verdict date, but many drugs warrant low investor confidence following poor clinical trial performance or negative FDA Advisory Committee (AdCom) meetings. 

Familiarity with the FDA regulatory landscape can yield great insight into event-triggered stock investing. Check out Bioassociate's latest report: FDA Stock Catalysts: Drug Approvals August - December 2013 for novel regulatory changes and for a breakdown of very interesting compounds still awaiting approval this year. 

more...
No comment yet.
Scooped by Bioassociate
Scoop.it!

2012: The Winners and Losers of the Pharmaceutical Industry – Summary Report Bioassociate Life Science & Biotech Consulting

2012: The Winners and Losers of the Pharmaceutical Industry – Summary Report Bioassociate Life Science & Biotech Consulting | Bioassociate Reports | Scoop.it

The financial performance of the biotechnology and healthcare indexes showed robust yield compared to the leading indexes, with the Nasdaq Biotechnology index returning ~35% growth YTD (more than 4 times that of the Dow Jones). For some of the publicly traded companies in the sector 2012 was an eventful year, with major achievements that were strongly reflected in their stock performance. The average return on investment this year for the top five companies was more than 350%, fueling up investors’ dreams.

This year we witnessed a bigger appetite for institutional funding when twelve new pharmaceutical companies entered the stock exchanges compared to the ten IPOs in 2011. The IPOs of 2012 were larger than last year, with Puma Biotechnology leading the pack with its mega IPO of $138M.

more...
No comment yet.
Scooped by Bioassociate
Scoop.it!

RedHill Biopharma Ltd: Q2 2013 Update Report Bioassociate Life Science & Biotech Consulting

RedHill Biopharma Ltd: Q2 2013 Update Report Bioassociate Life Science & Biotech Consulting | Bioassociate Reports | Scoop.it

RedHill Biopharma Ltd. (“the Company” and/or “RedHill”) is a publically traded pharmaceutical company focused on the development of late clinical-stage drug candidates, based on improved formulations and combinations of existing drugs. The Company is advancing the clinical development of its programs through the FDA’s 505(b)(2) regulatory pathway, which allows lowered development risks and costs, along with faster time to market.

RedHill is currently advancing 6 clinical programs; two of which are expected to be reviewed by the FDA during 2014, and three are entering pivotal clinical studies. The Company aims to find strategic partners for the marketing and distribution of its products.

The Q2 update report features the latest developments, amongst which are recent FDA applications, approvals and commencement of clinical studies.

more...
No comment yet.
Scooped by Bioassociate
Scoop.it!

Pharmerging Markets: China – the Next Innovative Pharma Market? Bioassociate Life Science & Biotech Consulting

Pharmerging Markets: China – the Next Innovative Pharma Market? Bioassociate Life Science & Biotech Consulting | Bioassociate Reports | Scoop.it

China: what has perhaps become one of the most persistent words in everyday lives across the globe. Aside from being colossal in size, powerful and significantly richer than most countries today, China is also on the brink of monumental change, more than ever threatening to reshape the world’s economy. Having gained immense momentum from being the manufacturing hub of the world, China has now reached the natural growth limitations of its imitative economy, and is on the brink of a transition towards becoming a global innovator. The government has set sights on the pharmaceutical industry as the leader of this transformation: the latest set of China’s five year plans is so elaborately focused on revamping and innovating the domestic pharma industry, that it has been named as one of the greatest government R&D initiatives of all time.

 

more...
No comment yet.
Scooped by Bioassociate
Scoop.it!

Israel’s Reign in the Golden Age of Neuroscience Bioassociate Life Science & Biotech Consulting

Israel’s Reign in the Golden Age of Neuroscience Bioassociate Life Science & Biotech Consulting | Bioassociate Reports | Scoop.it
Life Science Consulting | Tech Scouting | Biotech Valuation | Investor Relations | Biotech Stocks
Bioassociate's insight:

The blind can see, the deaf can hear, and the paralyzed can walk—without a doubt, the Golden Age of Neuroscience is upon us. And if that weren’t enough, mind control, telepathy and in fact elaborate real-life Avatar scenarios are so nigh that scores of the neurotech-savvy have begun to pre-order their titanium thought defense helmets. So awesome have the leaps of neurotechnology been in recent years that the media has struggled to deliver this industry a deserved timely coverage, and public awareness has just barely caught up with humanity’s neuro-prowess of late.

more...
No comment yet.